Compile Data Set for Download or QSAR
Report error Found 92 Enz. Inhib. hit(s) with all data for entry = 8831
TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421835(US10493060, Example GDC-0994)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421843(US10493060, Example 6 | US10525036, Example 6 | 7-...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421840(US10493060, Example 3 | US10525036, Example 3 | 2-...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421840(US10493060, Example 3 | US10525036, Example 3 | 2-...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421837(US10493060, Example SCH772984)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421838(US10493060, Example 1 | US10525036, Example 1 | 2-...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421838(US10493060, Example 1 | US10525036, Example 1 | 2-...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421835(US10493060, Example GDC-0994)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421836(US10493060, Example BVD-523)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421836(US10493060, Example BVD-523)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421837(US10493060, Example SCH772984)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421849(US10493060, Example 12 | US10525036, Example 12 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421851(US10493060, Example 14 | US10525036, Example 14 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421847(US10493060, Example 10 | (S)-2-(3-(6-Isopropoxypyr...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421849(US10493060, Example 12 | US10525036, Example 12 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421845(US10493060, Example 8 | US10525036, Example 8 | (S...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421846(US10493060, Example 9 | US10525036, Example 9 | (R...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421847(US10493060, Example 10 | (S)-2-(3-(6-Isopropoxypyr...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421843(US10493060, Example 6 | US10525036, Example 6 | 7-...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421844(US10493060, Example 7 | US10525036, Example 7 | 7-...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421844(US10493060, Example 7 | US10525036, Example 7 | 7-...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421845(US10493060, Example 8 | US10525036, Example 8 | (S...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421857(US10493060, Example 20 | US10525036, Example 20 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421859(US10493060, Example 22 | US10525036, Example 22 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421855(US10493060, Example 18 | US10525036, Example 18 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421856(US10493060, Example 19 | US10525036, Example 19 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421856(US10493060, Example 19 | US10525036, Example 19 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421857(US10493060, Example 20 | US10525036, Example 20 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421853(US10493060, Example 16 | US10525036, Example 16 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421854(US10493060, Example 17 | US10525036, Example 17 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421854(US10493060, Example 17 | US10525036, Example 17 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421855(US10493060, Example 18 | US10525036, Example 18 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421851(US10493060, Example 14 | US10525036, Example 14 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421852(US10493060, Example 15 | US10525036, Example 15 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421852(US10493060, Example 15 | US10525036, Example 15 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421853(US10493060, Example 16 | US10525036, Example 16 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421866(US10493060, Example 29 | US10525036, Example 29 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421866(US10493060, Example 29 | US10525036, Example 29 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421867(US10493060, Example 30 | US10525036, Example 30 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421867(US10493060, Example 30 | US10525036, Example 30 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421865(US10493060, Example 28 | US10525036, Example 28 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421865(US10493060, Example 28 | US10525036, Example 28 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421861(US10493060, Example 24 | US10525036, Example 24 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421863(US10493060, Example 26 | US10525036, Example 26 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421859(US10493060, Example 22 | US10525036, Example 22 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421860(US10493060, Example 23 | US10525036, Example 23 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421860(US10493060, Example 23 | US10525036, Example 23 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421880(US10493060, Example 45 | US10525036, Example 45 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421881(US10493060, Example 46 | US10525036, Example 46 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421882(US10493060, Example 47 | US10525036, Example 47 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/2/2020
Entry Details
US Patent

Displayed 1 to 50 (of 92 total ) | Next | Last >>
Jump to: